argenx to Present at TD Cowen 45th Annual Healthcare Conference

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, which is available in multiple regions including the U.S., Japan, Israel, the EU, the UK, China, and Canada [3] - argenx is actively evaluating its drug efgartigimod in various serious autoimmune diseases and is advancing several earlier-stage experimental medicines within its therapeutic franchises [3] Upcoming Events - Tim Van Hauwermeiren, the Chief Executive Officer of argenx, will present at the TD Cowen 45 Annual Healthcare Conference on March 3, 2025, at 11:50 a.m. ET [1] - A live webcast of the presentation will be accessible on the Investors section of the argenx website, with a replay available for approximately 30 days post-presentation [2]